688 related articles for article (PubMed ID: 30844611)
1. Ocrelizumab infusion experience in patients with relapsing and primary progressive multiple sclerosis: Results from the phase 3 randomized OPERA I, OPERA II, and ORATORIO studies.
Mayer L; Kappos L; Racke MK; Rammohan K; Traboulsee A; Hauser SL; Julian L; Köndgen H; Li C; Napieralski J; Zheng H; Wolinsky JS
Mult Scler Relat Disord; 2019 May; 30():236-243. PubMed ID: 30844611
[TBL] [Abstract][Full Text] [Related]
2. Long-term follow-up from the ORATORIO trial of ocrelizumab for primary progressive multiple sclerosis: a post-hoc analysis from the ongoing open-label extension of the randomised, placebo-controlled, phase 3 trial.
Wolinsky JS; Arnold DL; Brochet B; Hartung HP; Montalban X; Naismith RT; Manfrini M; Overell J; Koendgen H; Sauter A; Bennett I; Hubeaux S; Kappos L; Hauser SL
Lancet Neurol; 2020 Dec; 19(12):998-1009. PubMed ID: 33129442
[TBL] [Abstract][Full Text] [Related]
3. Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis.
Hauser SL; Bar-Or A; Comi G; Giovannoni G; Hartung HP; Hemmer B; Lublin F; Montalban X; Rammohan KW; Selmaj K; Traboulsee A; Wolinsky JS; Arnold DL; Klingelschmitt G; Masterman D; Fontoura P; Belachew S; Chin P; Mairon N; Garren H; Kappos L;
N Engl J Med; 2017 Jan; 376(3):221-234. PubMed ID: 28002679
[TBL] [Abstract][Full Text] [Related]
4. Ocrelizumab efficacy in subgroups of patients with relapsing multiple sclerosis.
Turner B; Cree BAC; Kappos L; Montalban X; Papeix C; Wolinsky JS; Buffels R; Fiore D; Garren H; Han J; Hauser SL
J Neurol; 2019 May; 266(5):1182-1193. PubMed ID: 30820738
[TBL] [Abstract][Full Text] [Related]
5. Ocrelizumab: A Review in Multiple Sclerosis.
Syed YY
CNS Drugs; 2018 Sep; 32(9):883-890. PubMed ID: 30171504
[TBL] [Abstract][Full Text] [Related]
6. Onset of clinical and MRI efficacy of ocrelizumab in relapsing multiple sclerosis.
Barkhof F; Kappos L; Wolinsky JS; Li DKB; Bar-Or A; Hartung HP; Belachew S; Han J; Julian L; Sauter A; Napieralski J; Koendgen H; Hauser SL
Neurology; 2019 Nov; 93(19):e1778-e1786. PubMed ID: 31484710
[TBL] [Abstract][Full Text] [Related]
7. Contribution of Relapse-Independent Progression vs Relapse-Associated Worsening to Overall Confirmed Disability Accumulation in Typical Relapsing Multiple Sclerosis in a Pooled Analysis of 2 Randomized Clinical Trials.
Kappos L; Wolinsky JS; Giovannoni G; Arnold DL; Wang Q; Bernasconi C; Model F; Koendgen H; Manfrini M; Belachew S; Hauser SL
JAMA Neurol; 2020 Sep; 77(9):1132-1140. PubMed ID: 32511687
[TBL] [Abstract][Full Text] [Related]
8. Ocrelizumab in relapsing and primary progressive multiple sclerosis: Pharmacokinetic and pharmacodynamic analyses of OPERA I, OPERA II and ORATORIO.
Gibiansky E; Petry C; Mercier F; Günther A; Herman A; Kappos L; Hauser S; Yamamoto Y; Wang Q; Model F; Kletzl H
Br J Clin Pharmacol; 2021 Jun; 87(6):2511-2520. PubMed ID: 33202059
[TBL] [Abstract][Full Text] [Related]
9. Shorter infusion time of ocrelizumab: Results from the randomized, double-blind ENSEMBLE PLUS substudy in patients with relapsing-remitting multiple sclerosis.
Hartung HP; Berger T; Bermel RA; Brochet B; Carroll WM; Holmøy T; Karabudak R; Killestein J; Nos C; Patti F; Ross AP; Vanopdenbosch L; Vollmer T; Buffels R; Garas M; Kadner K; Manfrini M; Wang Q; Freedman MS
Mult Scler Relat Disord; 2020 Nov; 46():102492. PubMed ID: 33039944
[TBL] [Abstract][Full Text] [Related]
10. Association of Higher Ocrelizumab Exposure With Reduced Disability Progression in Multiple Sclerosis.
Hauser SL; Bar-Or A; Weber MS; Kletzl H; Günther A; Manfrini M; Model F; Mercier F; Petry C; Wing Q; Koendgen H; Smith T; Kappos L
Neurol Neuroimmunol Neuroinflamm; 2023 Mar; 10(2):. PubMed ID: 36792367
[TBL] [Abstract][Full Text] [Related]
11. Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis.
Montalban X; Hauser SL; Kappos L; Arnold DL; Bar-Or A; Comi G; de Seze J; Giovannoni G; Hartung HP; Hemmer B; Lublin F; Rammohan KW; Selmaj K; Traboulsee A; Sauter A; Masterman D; Fontoura P; Belachew S; Garren H; Mairon N; Chin P; Wolinsky JS;
N Engl J Med; 2017 Jan; 376(3):209-220. PubMed ID: 28002688
[TBL] [Abstract][Full Text] [Related]
12. Effectiveness of Ocrelizumab in Primary Progressive Multiple Sclerosis: a Multicenter, Retrospective, Real-world Study (OPPORTUNITY).
Chisari CG; Bianco A; Brescia Morra V; Calabrese M; Capone F; Cavalla P; Chiavazza C; Comi C; Danni M; Filippi M; Iaffaldano P; Lanzillo R; Lo Fermo S; Lucisano A; Lugaresi A; Lus G; Marfia GA; Marinelli F; Mirabella M; Moiola L; Perin C; Realmuto S; Toscano S; Trojano M; Vecchio D; Patti F;
Neurotherapeutics; 2023 Oct; 20(6):1696-1706. PubMed ID: 37610702
[TBL] [Abstract][Full Text] [Related]
13. Ocrelizumab Treatment in Patients with Primary Progressive Multiple Sclerosis: Short-term Safety Results from a Compassionate Use Programme in Germany.
Rauer S; Hoshi MM; Pul R; Wahl M; Schwab M; Haas J; Ellrichmann G; Krumbholz M; Tackenberg B; Saum KU; Buck F; Leemhuis J; Kretschmann A; Aktas O
Clin Neurol Neurosurg; 2020 Oct; 197():106142. PubMed ID: 32920498
[TBL] [Abstract][Full Text] [Related]
14. Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial.
Kappos L; Li D; Calabresi PA; O'Connor P; Bar-Or A; Barkhof F; Yin M; Leppert D; Glanzman R; Tinbergen J; Hauser SL
Lancet; 2011 Nov; 378(9805):1779-87. PubMed ID: 22047971
[TBL] [Abstract][Full Text] [Related]
15. Ocrelizumab reduces thalamic volume loss in patients with RMS and PPMS.
Arnold DL; Sprenger T; Bar-Or A; Wolinsky JS; Kappos L; Kolind S; Bonati U; Magon S; van Beek J; Koendgen H; Bortolami O; Bernasconi C; Gaetano L; Traboulsee A
Mult Scler; 2022 Oct; 28(12):1927-1936. PubMed ID: 35672926
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness analysis of ocrelizumab versus subcutaneous interferon beta-1a for the treatment of relapsing multiple sclerosis.
Yang H; Duchesneau E; Foster R; Guerin A; Ma E; Thomas NP
J Med Econ; 2017 Oct; 20(10):1056-1065. PubMed ID: 28703659
[TBL] [Abstract][Full Text] [Related]
17. Comparing infusion-related reactions of the first full dose (600 mg) biosimilar ocrelizumab administration with the standard divided protocol in multiple sclerosis patients: a randomized controlled trial study.
Abbasi Kasbi N; Ghadiri F; Sahraian MA; Nahayati MA; Moghadasi AN; Langroodi HG; Poursadeghfard M; Hosseini S; Heidari H; Baghbanian SM; Kamali H; Ameli Z; Shahmohammadi S; Navardi S
Acta Neurol Belg; 2024 Feb; 124(1):205-212. PubMed ID: 37715074
[TBL] [Abstract][Full Text] [Related]
18. Single-arm study to assess comprehensive infusion guidance for the prevention and management of the infusion associated reactions (IARs) in relapsing-remitting multiple sclerosis (RRMS) patients treated with alemtuzumab (EMERALD).
Vukusic S; Brassat D; de Seze J; Izquierdo G; Lysandropoulos A; Moll W; Vanopdenbosch L; Arque MJ; Kertous M; Rufi P; Oreja-Guevara C
Mult Scler Relat Disord; 2019 Apr; 29():7-14. PubMed ID: 30654246
[TBL] [Abstract][Full Text] [Related]
19. An exploratory analysis of the efficacy of ocrelizumab in patients with multiple sclerosis with increased disability.
Wolinsky JS; Engmann NJ; Pei J; Pradhan A; Markowitz C; Fox EJ
Mult Scler J Exp Transl Clin; 2020; 6(1):2055217320911939. PubMed ID: 32206332
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of ocrelizumab vs interferon beta-1a in participants of African descent with relapsing multiple sclerosis in the Phase III OPERA I and OPERA II studies.
Cree BAC; Pradhan A; Pei J; Williams MJ;
Mult Scler Relat Disord; 2021 Jul; 52():103010. PubMed ID: 34147885
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
